September 10, 2025Sains MalaysianaOpen Access

EGFR-Directed Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer

View Full Paper

Ask AI

Bookmark

EGFR tyrosine kinase inhibitors significantly improve overall survival in patients with non-small cell lung cancer, addressing critical treatment needs.
Overcoming resistance mutations like T790M has spurred the development of newer EGFR-directed therapies, improving patient outcomes.
The review discusses economic barriers in accessing EGFR-targeted treatments, especially in low- and middle-income countries.
Advancements in combination therapies for NSCLC offer strategies to combat resistance, but costs remain a significant limitation.

Discussion

No takes yet. Share an insight, caveat, or question.

Review reveals how EGFR mutations change outcomes in non-small cell lung cancer, highlighting treatment challenges.

Sidek et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark